The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 08, 2022

Filed:

Oct. 15, 2021
Applicant:

The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US);

Inventors:

Daniel P. Dever, Stanford, CA (US);

Rasmus O. Bak, Stanford, CA (US);

Ayal Hendel, Stanford, CA (US);

Waracharee Srifa, Stanford, CA (US);

Matthew H. Porteus, Stanford, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/90 (2006.01); C12N 9/22 (2006.01); C07K 14/805 (2006.01); A61K 35/28 (2015.01); A61K 48/00 (2006.01); C12N 5/0789 (2010.01); C12N 15/85 (2006.01); A61P 7/00 (2006.01); A61K 31/7115 (2006.01); C12N 5/0781 (2010.01); C12N 5/0783 (2010.01); C12N 5/0775 (2010.01); C12N 15/113 (2010.01); C12N 15/864 (2006.01);
U.S. Cl.
CPC ...
C12N 15/907 (2013.01); A61K 31/7115 (2013.01); A61K 35/28 (2013.01); A61K 48/00 (2013.01); A61P 7/00 (2018.01); C07K 14/805 (2013.01); C12N 5/0635 (2013.01); C12N 5/0636 (2013.01); C12N 5/0647 (2013.01); C12N 5/0665 (2013.01); C12N 9/22 (2013.01); C12N 15/113 (2013.01); C12N 15/85 (2013.01); C12N 15/8645 (2013.01); C12N 2310/20 (2017.05); C12N 2310/311 (2013.01); C12N 2310/313 (2013.01); C12N 2310/3125 (2013.01); C12N 2750/14143 (2013.01);
Abstract

In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.


Find Patent Forward Citations

Loading…